Bausch Health Companies Inc. (TSE:BHC - Free Report) - Investment analysts at Zacks Research lifted their FY2024 EPS estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will earn $4.98 per share for the year, up from their prior estimate of $4.88. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2024 earnings at $1.50 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.56 EPS, Q4 2025 earnings at $1.73 EPS, FY2025 earnings at $5.77 EPS, Q1 2026 earnings at $1.50 EPS and Q2 2026 earnings at $1.50 EPS.
Bausch Health Companies (TSE:BHC - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of C$1.22. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 2,304.54%. The firm had revenue of C$3.29 billion for the quarter, compared to analyst estimates of C$3.20 billion.
BHC has been the topic of a number of other research reports. Evercore ISI upgraded shares of Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th. Raymond James upgraded shares of Bausch Health Companies to a "hold" rating in a research report on Wednesday, July 10th.
Read Our Latest Analysis on BHC
Bausch Health Companies Stock Performance
Shares of TSE:BHC traded up C$0.08 on Thursday, reaching C$11.26. 126,605 shares of the company's stock were exchanged, compared to its average volume of 376,588. The company has a fifty day moving average of C$9.50 and a 200-day moving average of C$9.95. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$15.43. The company has a market capitalization of C$4.13 billion, a price-to-earnings ratio of -6.39, a PEG ratio of 0.21 and a beta of 0.77. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76.
Insider Buying and Selling
In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is currently owned by company insiders.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Featured Articles
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
